Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29534248 | 1.00 | PTK2 (0.54) | PTK2TDP1MEN1KMT2ACA1 | |
| SCHEMBL15337919 | 0.85 | PTK2 (0.38) | PTK2CA1CA2CA9CA12 | |
| SCHEMBL10027390 | 0.83 | PTK2 (0.43) | PTK2TDP1MEN1KMT2ACA1 | |
| SCHEMBL30391007 | 0.77 | PTK2 (0.39) | PTK2CA1CA2CA9ALDH1A1 | |
| SCHEMBL2264764 | 0.77 | GAA (0.53) | PTK2TDP1CA1CA2CA9 | |
| SCHEMBL23041366 | 0.77 | CD44 (0.48) | PTK2TDP1CYP3A4ALOX15SMN1; SMN2 | |
| SCHEMBL19884912 | 0.77 | PTK2 (0.39) | PTK2CA1CA2CA9ALDH1A1 | |
| SCHEMBL17298240 | 0.77 | CYP3A4 (0.55) | TDP1MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL30490095 | 0.77 | GAA (0.53) | PTK2TDP1CA1CA2CA9 | |
| SCHEMBL19692692 | 0.72 | PTK2 (0.33) | PTK2CA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11772085-B2 | Far superior oxidation catalysts based on macrocyclic compounds | CARNEGIE MELLON UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-11446294-B2 | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy | LU QING BIN (CA) | 2022-09-20 | — | — | US | disclosed |
| EP-4015511-A1 | OXIDATION CATALYSTS BASED ON MACROCYCLIC COMPOUNDS | CARNEGIE MELLON UNIVERSITY (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114380700-A | Non-platinum based anti-cancer compounds for targeted chemotherapy | 卢庆彬 | 2022-04-22 | — | — | CN | disclosed |
| EP-3578176-A1 | NON-PLATINUM-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY | Lu, Qing-Bin (CA) | 2019-12-11 | — | — | EP | disclosed |
| EP-2935215-B1 | RADIOSENSITIZER COMPOUNDS FOR USE IN COMBINATION WITH RADIATION | LU QING BIN (CA) | 2019-11-13 | — | — | EP | disclosed |
| EP-3055287-B1 | NON-PLATINUM-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY | LU QING BIN (CA) | 2019-11-06 | — | — | EP | disclosed |
| US-10463662-B2 | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy | LU QING BIN (CA) | 2019-11-05 | — | — | US | disclosed |
| US-10463662-B2 | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy | LU QING BIN (CA) | 2019-11-05 | — | — | US | disclosed |
| US-9655965-B2 | Radiosensitizer compounds for use in combination with radiation | Lu qing-bin (CA) | 2017-05-23 | — | — | US | disclosed |
| US-20110015388-A1 | Substituted benzazoloporphyrazines for polymerization and surface attachment and articles formed therefrom | UNITED STATES DEPARTMENT OF ENERGY | 2011-01-20 | — | — | US | disclosed |
| US-20110015388-A1 | Substituted benzazoloporphyrazines for polymerization and surface attachment and articles formed therefrom | UNITED STATES DEPARTMENT OF ENERGY | 2011-01-20 | — | — | US | disclosed |
| US-20110015388-A1 | Substituted benzazoloporphyrazines for polymerization and surface attachment and articles formed therefrom | UNITED STATES DEPARTMENT OF ENERGY | 2011-01-20 | — | — | US | disclosed |
| US-20090065057-A1 | Charge-Transport Materials, Methods of Fabrication Thereof, and Methods of Use Thereof | GEORGIA TECH RESEARCH CORPORATION | 2009-03-12 | — | — | US | disclosed |
| WO-2005123737-A9 | CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF | TY OF ARIZONA ARIZONA BOARD OF (US) | 2006-04-06 | — | — | WO | disclosed |
| WO-2005123737-A2 | CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-12-29 | — | — | WO | disclosed |
| EP-0029658-A1 | Salts of dihalo-2-quinoxaline carboxylic acids, their preparation and pharmaceutical formulations containing them | ELI LILLY AND COMPANY (US) | 1981-06-03 | — | — | EP | disclosed |
| US-4264600-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-04-28 | — | — | US | disclosed |
| US-4252954-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-02-24 | — | — | US | disclosed |
| EP-0010426-A1 | Pharmaceutical composition containing 3,4-dihydro-3-oxo-2-quinoxalines, novel such quinoxalines and processes for the production thereof | ELI LILLY AND COMPANY (US) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11772085-B2 | Far superior oxidation catalysts based on macrocyclic compounds | SOD1, ME3, ME2 | PTK2 3488/4885TDP1 2577/4885MEN1 848/4885 |
| US-10463662-B2 | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy | TOP2B, POLR2B, RB1 | PTK2 2691/4885TDP1 1110/4885MEN1 3852/4885 |
| US-20090065057-A1 | Charge-Transport Materials, Methods of Fabrication Thereof, and Methods of Use Thereof | SLC9A3, SLC18A2, SLC9A2 | PTK2 1963/4885TDP1 1229/4885MEN1 1440/4885 |
| US-11446294-B2 | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy | TOP2B, RB1, POLR2B | PTK2 2631/4885TDP1 1086/4885MEN1 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.